Clinical Trial Update: A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Obicetrapib/ezetimibe 10 mg fixed-dose combination or Obicetrapib 10 mg daily on top of guideline-recommended lipid-lowering therapy in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Metabolic Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• Obicetrapib (obicetrapib)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Lipidemia, Type 2 Diabetes (T2DM) | Phase 3 | Status: RECRUITING